Pulmatrix Hastens COPD Trials Via $14M Series B1 Financing
By Jennifer Boggs
Tuesday, August 16, 2011
Pulmatrix Inc. topped off its 2009 $30 million Series B with another $14 million to accelerate development of PUR118, its lead iCALM candidate, through Phase IIa studies in chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.